Abstract 2085
Background
Donor lymphocyte infusions (DLI) become one of the currently used approaches to treat post-transplant relapses. However, the wide use of the different DLI strategies, its effectivity and toxicity are still unpredictable in many patients. We evaluated the impact of DLI for patients with myeloid neoplasms experienced relapse post hematopoietic stem cell transplantation (HSCT).
Methods
This study included patients with myeloid neoplasms who received DLI post HSCT at the BMT unit, Children Cancer Hospital Egypt (CCHE-57357) from 2009 to 2017. DLI was given for patients with either rising minimal residual disease (MRD) or after systemic chemotherapy for those who experienced frank relapse.
Results
A total of 20 patients received post HSCT DLI were analyzed, with median age of 7 years. About 12 patients (60%) had acute myeloid leukemia (AML), 5 with chronic myeloid leukemia (CML) and 3 cases had myelodysplastic syndrome (MDS). Seven patients had frank relapse and given systemic chemotherapy followed by DLI upon complete remission, while 13 patients received only DLI due to rising MRD. Early relapse (during 1st year) was reported in 14 cases (70%) and 7 patients relapsed beyond 1st year post-transplant. Regarding the graft status at relapse, 15 patients had maintained complete chimera while 5 patients showed mixed chimera. The one-year disease free survival (DFS) and overall survival (OS) post DLI for the whole cohort were 54% and 64%, respectively with one patient had a non-relapse mortality and 6 patients developed graft versus host disease (GvHD) post DLI. According the initial diagnosis, DFS at one year was 80% for CML, 66% for MDS and 41% for AML patients. Also DFS was better for those with late relapse (70% vs 57% for early relapse) and for those who developed GvHD post DLI.
Conclusions
DLI was associated with a durable efficacy and low toxicity in pediatric patients with hematologic malignancies. However, larger studies and standardized approaches are required to identify the outcome predictors of this treatment modality.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1701 - Immunogenicity and optimal timing of 13-valent pneumococcal conjugate vaccination during adjuvant chemotherapy in gastric and colorectal cancer : A randomized controlled trial
Presenter: Wonyoung Choi
Session: Poster Display session 1
Resources:
Abstract
3158 - Tobacco Retail Access and Tobacco Cessation Among Head and Neck Cancer (HNC) Survivors
Presenter: Lawson Eng
Session: Poster Display session 1
Resources:
Abstract
5511 - ASSERT: A Prospective, Observational Study Measuring Sodium Improvement and Outcomes in Patients Treated for Moderate to Severe Hyponatremia Secondary to Syndrome of Inappropriate Antidiuretic Hormone secretion (SIADH) in Italy (Lung Cancer Cohort)
Presenter: Rossana Berardi
Session: Poster Display session 1
Resources:
Abstract
3821 - Efficacy and safety of controlled ovarian stimulation with or without letrozole co-administration for fertility preservation: A systematic review and meta-analysis.
Presenter: Benedetta Bonardi
Session: Poster Display session 1
Resources:
Abstract
2168 - Child development at 6 years after maternal cancer diagnosis and treatment during pregnancy
Presenter: Tineke Vandenbroucke
Session: Poster Display session 1
Resources:
Abstract
5855 - Update of the registry of young women with cancer by the International Network of Cancer, Infertility and Pregnancy
Presenter: Charlotte Maggen
Session: Poster Display session 1
Resources:
Abstract
5156 - Erectile dysfunction in patients with metastatic renal cell carcinoma
Presenter: Ilya Tsimafeyeu
Session: Poster Display session 1
Resources:
Abstract
4992 - Exercise level, interest and preferences in cancer patients.
Presenter: Alice Avancini
Session: Poster Display session 1
Resources:
Abstract
3427 - Filling the Gaps in Informed Consent for Advanced Cancer Patients considering Phase 1 Oncology Trials - an in-depth Qualitative Study of Key Stakeholders at a large United Kingdom Phase 1 unit
Presenter: Abhijit Pal
Session: Poster Display session 1
Resources:
Abstract
3537 - Breast Cancer Patients’ Quality of Life: Real World Data
Presenter: Thanos Kosmidis
Session: Poster Display session 1
Resources:
Abstract